Spironolactone-d6-1 is a deuterium-labeled version of Spironolactone. Spironolactone functions as an aldosterone antagonist, targeting mineralocorticoid receptors (IC50=24 nM) and androgen receptors (IC50=77 nM). It promotes podocyte autophagy (autophagy) and modulates pain. The compound improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II-induced inflammation. It also decreases aldosterone-induced vascular and soft tissue calcification via PIT1-dependent signaling, and mitigates vascular dysfunction in type II diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. At low concentrations, Spironolactone and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca2+ channels to exert antihypertensive effects.